Suppliers and packagers for generic pharmaceutical drug: pramlintide acetate

pramlintide acetate

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332	NDA	AstraZeneca Pharmaceuticals LP	0310-6615-02	2 CARTRIDGE in 1 CARTON (0310-6615-02) / 1.5 mL in 1 CARTRIDGE	2015-01-08
Astrazeneca Ab	SYMLIN	pramlintide acetate	INJECTABLE;SUBCUTANEOUS	021332	NDA	AstraZeneca Pharmaceuticals LP	0310-6627-02	2 CARTRIDGE in 1 CARTON (0310-6627-02) / 2.7 mL in 1 CARTRIDGE	2015-01-08

Pramlintide Acetate Suppliers: Supply Chain Analysis

Last updated: February 19, 2026

This report analyzes the current landscape of suppliers for pramlintide acetate, a synthetic analog of human amylin used in the treatment of type 1 and type 2 diabetes. The analysis identifies key manufacturers, their production capabilities, and relevant patent and regulatory considerations impacting supply chain stability.

Who Manufactures Pramlintide Acetate?

Pramlintide acetate is primarily manufactured by contract development and manufacturing organizations (CDMOs) and specialized peptide synthesis companies. The complexity of peptide synthesis and purification requires advanced technical expertise and specialized facilities. The primary active pharmaceutical ingredient (API) manufacturer for the originator product, SymlinPen®, was originally Amylin Pharmaceuticals, which was acquired by Bristol Myers Squibb, and subsequently the diabetes franchise was sold to AstraZeneca. However, the current API manufacturing for commercial supply is largely handled by third-party CDMOs.

Key Players in Peptide API Manufacturing Relevant to Pramlintide Acetate:

• Bachem AG: A leading global manufacturer of peptides and oligonucleotides. Bachem has extensive experience in the synthesis and cGMP manufacturing of complex peptides. They possess the scale and regulatory compliance required for pharmaceutical API production.
• PolyPeptide Group: Another significant player in peptide synthesis, with multiple manufacturing sites globally. PolyPeptide offers custom synthesis services and has a strong track record in producing APIs for various therapeutic areas, including metabolic diseases.
• CPC Scientific: Specializes in custom peptide synthesis and is known for its flexibility and ability to handle complex peptide sequences. While potentially serving smaller-scale or development needs, they can be a source for specialized peptide manufacturing.
• Other CDMOs with Peptide Capabilities: A number of other CDMOs possess peptide synthesis capabilities. Companies like Lonza, CordenPharma, and MilliporeSigma (through its EMD Millipore division) offer broader drug substance manufacturing services, which can include peptide APIs depending on their specific technology platforms and current capacity.

The specific manufacturer(s) producing the API for current commercial SymlinPen® are not publicly disclosed by AstraZeneca. However, the above entities represent the types of organizations with the technical and regulatory capacity to produce pramlintide acetate API under current Good Manufacturing Practices (cGMP).

What are the Technical Requirements for Pramlintide Acetate Synthesis?

Pramlintide acetate is a 37-amino acid peptide with specific post-translational modifications and salt formation. Its synthesis is a multi-step process involving solid-phase peptide synthesis (SPPS) or liquid-phase peptide synthesis (LPPS), followed by purification and acetylation.

Key Synthesis and Manufacturing Considerations:

• Peptide Sequence Complexity: Pramlintide has a sequence of: H-Ser-Asn-Lys-Gly-Ala-Ile-Asp-Phe-Phe-His-Lys-Gln-Tyr-Pro-Ser-Asn-Ala-Val-Ala-Asp-Val-Gly-Thr-Ala-Gln-Leu-Ala-Ala-Gln-Ser-Gly-Gly-Pro-Gly-Gly-Ser-Asn-OH. The specific arrangement and number of amino acids present a challenge for efficient and accurate synthesis.
• Disulfide Bond Formation: Pramlintide contains a critical disulfide bond between Cysteine residues at positions 2 and 7, mimicking a feature of native amylin. Precise control of oxidation conditions is necessary to form this bond correctly.
• Purification: Achieving the high purity required for pharmaceutical APIs (typically >98% or higher) necessitates advanced purification techniques such as High-Performance Liquid Chromatography (HPLC), often reverse-phase HPLC. Multiple purification steps are usually employed.
• Acetylation: The acetate salt form requires specific salt formation procedures to ensure stability and bioavailability.
• cGMP Compliance: All manufacturing must adhere to strict cGMP regulations enforced by bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes robust quality control, process validation, and documentation.
• Scale-Up Challenges: Transitioning from laboratory-scale synthesis to commercial-scale production involves significant process optimization to maintain yield, purity, and cost-effectiveness.

The synthesis process is proprietary, and specific details regarding intermediate steps and reagents are held by the manufacturers. However, the general methodologies for peptide synthesis are well-established in the industry.

What is the Patent Landscape for Pramlintide Acetate?

The patent landscape for pramlintide acetate is complex, involving patents on the molecule itself, its uses, formulations, and manufacturing processes. The originator patents have largely expired, paving the way for potential generic competition and new intellectual property around improved manufacturing or delivery methods.

Key Patent Expirations and Developments:

• Composition of Matter Patents: The foundational patents covering the pramlintide molecule itself have expired. For example, U.S. Patent 4,816,574, assigned to Amylin Pharmaceuticals, which claimed synthetic amylin analogs including pramlintide, expired in 2007.
• Use Patents: Patents covering the therapeutic uses of pramlintide, such as for improving glycemic control in patients with diabetes, have also expired.
• Formulation Patents: While core formulation patents may have expired, there can be ongoing patents related to specific delivery devices, extended-release formulations, or novel combinations that could extend market exclusivity. For instance, patents relating to pen devices or specific excipients used in formulations could be relevant.
• Manufacturing Process Patents: While composition of matter patents expire, manufacturers may hold patents on novel or improved synthetic routes, purification methods, or crystallization processes that offer advantages in terms of yield, purity, cost, or environmental impact. These can provide a degree of protection even after core molecule patents expire.
• Generic and Biosimilar Activity: The expiration of key patents generally allows for the development and submission of Abbreviated New Drug Applications (ANDAs) for generic versions or Biologics License Applications (BLAs) if the product were classified as a biologic. However, pramlintide is a chemically synthesized peptide, making it a candidate for generic drug development under ANDA pathways. The development of generic pramlintide acetate is underway by several pharmaceutical companies.

The expiry of primary patents has opened opportunities for generic manufacturers. However, navigating existing and newly filed process and formulation patents is crucial for any company looking to enter the market.

What are the Regulatory Considerations for Pramlintide Acetate Supply?

The supply of pramlintide acetate is governed by stringent regulatory requirements from health authorities worldwide. Compliance with these regulations is critical for API manufacturers and finished drug product manufacturers.

Key Regulatory Bodies and Requirements:

• U.S. Food and Drug Administration (FDA):
  • cGMP Compliance: API manufacturers must comply with 21 CFR Part 210 and 211, detailing Current Good Manufacturing Practices. This includes robust quality management systems, process validation, analytical testing, and stability programs.
  • Drug Master File (DMF): API manufacturers typically file a DMF with the FDA, providing confidential detailed information about facilities, processes, and materials used in manufacturing, processing, packaging, and storing of the drug substance. This allows regulatory agencies to review proprietary API information without disclosing it to the drug product applicant.
  • Site Inspections: FDA conducts regular inspections of manufacturing facilities to ensure ongoing cGMP compliance.
• European Medicines Agency (EMA):
  • EudraLex Volume 4: Similar to FDA cGMP, EMA regulations outline GMP requirements for medicinal products and active substances.
  • Certificate of Suitability (CEP): For APIs, a CEP issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM) can demonstrate compliance with the European Pharmacopoeia monograph and facilitate regulatory approval in Europe.
  • Inspections: EMA and national competent authorities conduct GMP inspections.
• Other International Agencies: Agencies such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, and Australia's Therapeutic Goods Administration (TGA) have their own cGMP guidelines and inspection processes.
• Pharmacopoeial Standards: Pramlintide acetate must meet the standards outlined in relevant pharmacopoeias, such as the United States Pharmacopoeia (USP) or the European Pharmacopoeia (Ph. Eur.), regarding identity, purity, strength, and quality.
• Impurity Control: Strict limits are placed on impurities, including process-related impurities, degradation products, and residual solvents. Identification and control of genotoxic impurities are particularly critical.
• Stability Studies: Comprehensive stability studies are required to establish the retest period for the API and the shelf life for the finished drug product under defined storage conditions.

For generic manufacturers, demonstrating bioequivalence of their finished product to the reference listed drug (SymlinPen®) is a primary regulatory hurdle, in addition to meeting all API and drug product manufacturing standards.

What is the Market Outlook for Pramlintide Acetate Supply?

The market for pramlintide acetate is influenced by several factors, including the prevalence of diabetes, the competitive landscape of diabetes treatments, patent expirations, and the introduction of generic alternatives.

Market Drivers and Constraints:

• Diabetes Prevalence: The growing global incidence of type 1 and type 2 diabetes continues to drive demand for therapeutic agents like pramlintide, particularly for patients who do not achieve optimal glycemic control with other therapies.
• Competition from GLP-1 Receptor Agonists: Pramlintide competes with a wide range of diabetes medications, including incretin mimetics like GLP-1 receptor agonists (e.g., liraglutide, semaglutide), which have demonstrated significant efficacy in glycemic control and weight management, and often have more convenient dosing regimens.
• Generic Entry: The expiration of key patents has created an opening for generic manufacturers. Successful generic launches typically lead to increased price competition and broader market access. This can increase overall volume but reduce per-unit revenue for the API manufacturer.
• Specialty Pharmacy Distribution: Pramlintide is often dispensed through specialty pharmacies due to its specific administration requirements and patient education needs, which can impact distribution channels and market penetration.
• Innovations in Delivery and Combination Therapies: Ongoing research into improved delivery systems (e.g., alternative injection devices, extended-release formulations) or combination therapies involving pramlintide could influence its long-term market position.
• Manufacturing Cost and Complexity: The cost of manufacturing complex peptides like pramlintide acetate remains a significant factor. While generic competition can drive down finished product prices, API manufacturers must maintain efficient and cost-effective production processes.

The market outlook suggests continued demand for pramlintide, especially in specific patient populations. However, the entry of generics will likely lead to price erosion. API suppliers must focus on cost competitiveness, robust quality assurance, and reliable supply chains to succeed.

Key Takeaways

• Pramlintide acetate API is primarily manufactured by specialized peptide CDMOs with advanced synthesis and cGMP capabilities, such as Bachem and PolyPeptide Group.
• The synthesis of pramlintide acetate is technically demanding, requiring expertise in peptide chemistry, disulfide bond formation, purification, and salt formation under strict cGMP conditions.
• While core composition of matter and use patents have expired, manufacturers must navigate process patents and the evolving IP landscape.
• Regulatory compliance with cGMP, pharmacopoeial standards, and impurity control is paramount for API suppliers, involving rigorous oversight from agencies like the FDA and EMA.
• The market for pramlintide acetate is shaped by the prevalence of diabetes, competition from other drug classes, and the impending impact of generic competition, which will likely increase volume but pressure prices.

FAQs

1. Are there any single-source suppliers for pramlintide acetate API? While specific commercial supply chains are proprietary, the nature of peptide manufacturing suggests that multiple qualified CDMOs exist, providing alternative sourcing options. Companies often qualify several suppliers to mitigate risk.

2. What are the typical lead times for custom peptide API manufacturing for a complex molecule like pramlintide acetate? Lead times can vary significantly, but for complex peptide APIs under cGMP, initial process development and validation can take 12-24 months or more. Routine commercial production batches typically have lead times of 3-6 months from order to delivery, depending on the manufacturer's capacity and backlog.

3. How does the cost of pramlintide acetate API compare to other peptide drugs? The cost is influenced by the length and complexity of the peptide sequence, the number of synthesis steps, purification yield, and regulatory compliance overhead. Pramlintide, being a 37-amino acid peptide with a disulfide bond, is considered moderately to highly complex, positioning its API cost in the mid-to-high range for peptide therapeutics.

4. What is the typical shelf life of pramlintide acetate API? The shelf life of a peptide API is determined by comprehensive stability studies. For well-characterized and properly stored peptide APIs like pramlintide acetate, a retest period of 2-3 years is common, provided it meets all specifications throughout this period.

5. What are the primary challenges in scaling up pramlintide acetate API manufacturing? Challenges include maintaining consistent purity and yield across larger batch sizes, efficient removal of impurities and side products, precise control of disulfide bond formation on a large scale, and ensuring homogeneity of the final acetate salt. Process optimization and robust analytical controls are critical for successful scale-up.

Citations

[1] U.S. Patent 4,816,574. (1989). Synthetic amylin analogs. Amylin Pharmaceuticals.